Skip to main content

Drug Interactions between dabigatran and idelalisib

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

dabigatran idelalisib

Applies to: dabigatran and idelalisib

MONITOR: Coadministration with idelalisib may increase the serum concentrations of drugs that are substrates of the P-glycoprotein (P-gp) efflux transporter, such as dabigatran etexilate. Data suggest that idelalisib does not inhibit systemic P-gp at clinically relevant doses; however, it may have an effect on sensitive P-gp substrates in the gastrointestinal tract due to higher local concentrations after an oral dose.

MANAGEMENT: Caution and close monitoring are advised if idelalisib is prescribed in combination with orally administered P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever idelalisib is added to or withdrawn from therapy.

References (2)
  1. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  2. (2014) "Product Information. Zydelig (idelalisib)." Gilead Sciences

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer